ScreenerHero
HomeScreenerChartsCompareGroupsMapsCommoditiesWatchlists·PricingBlog
Create free account
Sign in
ScreenerHero

The most complete stock screener for serious investors. 18,000+ stocks across US, Canada, Europe & Australia.

All systems operational
Tools
  • Screener
  • Maps
  • Commodities
  • Charts
  • Watchlists
  • Alerts
  • Calendar
  • Portfolio
Screeners
  • US & Canada
  • Nordic
  • Benelux
  • Dividend EU
  • Value EU
  • Microcap EU
  • Small Cap EU
  • Investor screens
Compare
  • vs Stockopedia
  • vs Finviz
  • vs Koyfin
  • vs TradingView
  • All comparisons
  • Alternatives
Company
  • About
  • Coverage
  • Blog
  • Help
  • Pricing
  • Affiliate Program
  • Terms of Service
  • Privacy Policy
Screeners by countryUKGermanyFranceSpainItalyNetherlandsSwitzerlandSwedenNorwayDenmarkFinlandBelgiumAustriaPortugalPolandGreeceTurkeyRomaniaCanadaMexicoAustraliaNew Zealand
Deutsch·Français·Español·Italiano

For informational and educational purposes only. Not financial advice. Market participation involves substantial risk of loss. Past performance does not guarantee future results. Always do your own research.

© 2026 ScreenerHero.com · All rights reserved
ScreenerHero

HBP Helix BioPharma Corp.

TSX · CA · Healthcare · Biotechnology · helixbiopharma.com
0.6291USD0.9000 CAD · TSX+4.65%Mkt Cap: 48.05M USDP/E: —3d ago

Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; LDOS007, which is in phase Ib/II for the treatment of lung cancer; and CEACAM6-targeting technology, provides multi-specific antibody-drug conjugates (ADCs) for gastrointestinal cancers and radioligand therapeutics for pancreatic cancer. It has collaboration agreements with Moffitt Cancer Center to investigate and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to investigate the effects of L DOS47 on tumor acidity using imaging technologies. The company has an agreement with metaShape Pharma AG for covering LEUMUNA, within the field of adipose tissue-related and metabolic diseases; and GEMCEDA, an oral gemcitabine prodrug combined with cedazuridine in preclinical development for the treatment of solid tumors. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.…

HBPHelix BioPharma Corp.
0.6291USD+4.65%

Industry Peers

Biotechnology
Screen all Biotechnology
VRTX
Vertex Pharmaceuticals Incorporated
$130.58BUSDP/E 33.1
REGN
Regeneron Pharmaceuticals, Inc.
$95.24BUSDP/E 20.4
MRNA
Moderna, Inc.
$78.90BUSD
CSL
CSL Limited
$63.11BUSD
ARGX
argenx SE
$58.94BUSDP/E 34.3
UCB
UCB SA
$58.59BUSDP/E 24.7
ARGX
argenx SE
$58.21BUSDP/E 32.1
ONC
BeOne Medicines AG
$44.66BUSDP/E 50.1
RPRX
Royalty Pharma plc
$39.36BUSDP/E 44.7
RVMD
Revolution Medicines, Inc.
$34.87BUSD
GMAB
Genmab A/S
$31.45BUSDP/E 46.1
GMAB
Genmab A/S
$31.20BUSDP/E 42.9
INSM
Insmed Incorporated
$31.01BUSD
ROIV
Roivant Sciences Ltd.
$28.01BUSD
INCY
Incyte Corporation
$23.36BUSDP/E 58.5
BNTX
BioNTech SE
$20.07BUSD
ALNY
Alnylam Pharmaceuticals, Inc.
$19.26BUSDP/E 7.3
ASND
Ascendis Pharma A/S
$16.58BUSDP/E 17.6
EXEL
Exelixis, Inc.
$15.77BUSDP/E 19.4
BBIO
BridgeBio Pharma, Inc.
$14.81BUSD